TB/HIV Dr Graham Cooke

Welcome to your TB/HIV Dr Graham Cooke

Which of the following statements is true?

a. Mycobacterium tuberculosis (MTB) is a disease that usually affects the lungs

b. The most common site of tuberculosis is the lymph nodes

c. A positive Mantoux skin test means a person has MTB in their body

d. Smear microscopy is the most commonly used test to diagnose tuberculosis

e. Latent TB infection always requires treatment to prevent progression to diseases

Which of the following is NOT true?

a The number of newly notified TB cases each year is going down in the UK

b. HIV prevalence in new TB cases in the UK is under 10%

c. Starting HIV treatment has little impact on risk of tuberculosis in people living with HIV

d. The sensitivity of immune based tests (IGRAS) to detect latent TB infection is affected by HIV

e. Smear microscopy is less sensitive for tuberculosis in HIV positive Individuals with low CD4 counts

Which of these is TRUE?

a. Co-administration of rifampicin requires dose adjustment of NRTIs, NNRTs and protease inhibitors

b. Rifabutin cannot be co-administered with protease inhibitors

c. Unmasking IRIS can be the consequence of undiagnosed subclinical tuberculosis

d. IRIS has a high mortality rate

e. There is no randomised evidence to support the use of steroids in IRIS

Which of the following are TRUE?

a. A rifampicin sensitive organism cannot be classified as MDR-TB

b. The most common monoresistance in the UK is to rifampicin

c. XDR-TB can still be sensitive to amikacin

d. Over 5% of tuberculosis in the UK is MDR-TB

e. There are fewer than 100 cases of MDR-TB notified in the UK each year

Which of these are TRUE?

a. Most drug resistance in the UK develops in patients who do not take their treatment as prescribed

b. Individualised treatment of MDR-TB is associated with better outcomes than standardised treatments

c. 20% of individuals hospitalised with MDR-TB in the UK lose their homes

d. Bedaquiline is the only new TB drug in the last 20 years

e. Linezolid is recommended by WHO as a first line treatment for MDR-TB